D. Boral Capital Reiterates “Buy” Rating for NeuroSense Therapeutics (NASDAQ:NRSN)

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $14.00 target price on the stock.

A number of other equities research analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Wednesday, November 19th. Zacks Research raised NeuroSense Therapeutics to a “hold” rating in a report on Wednesday, October 15th. Finally, Noble Financial upgraded NeuroSense Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

NeuroSense Therapeutics Price Performance

NASDAQ:NRSN opened at $1.04 on Monday. NeuroSense Therapeutics has a twelve month low of $0.80 and a twelve month high of $2.60. The company’s 50 day moving average is $1.14 and its two-hundred day moving average is $1.46.

Hedge Funds Weigh In On NeuroSense Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC grew its holdings in NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares during the period. Jane Street Group LLC purchased a new stake in NeuroSense Therapeutics in the 2nd quarter worth approximately $54,000. Finally, Two Sigma Investments LP acquired a new stake in shares of NeuroSense Therapeutics during the 3rd quarter worth approximately $26,000. Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.